PF4 Antibody Persistence and Long-term Pathogenicity in VITT
Anand Padmanabhan, Professor and Consultant at Mayo Clinic, shared on LinkedIn:
”Congrats to Adam Kanack, Emily Mauch, Guillaume Roberge, and coauthors related to their study on long-term persistence and pathogenicity of VITT antibodies.
Key points:
– Despite clonal restriction of Anti-PF4 abs in VITT, unlike MGTS, these monoclonal spikes are not seen when the entire IgG repertoire is examined. You unmask anti-PF4 clonal restriction only when you isolate the anti-PF4 antibodies
– In some cases, VITT abs can comprise kappa light chains (dogma to date is that it can only be lambda)
– As shown in a case in our report, thrombocytopenia can persist for more than 4 years.”
Read the full article here.
Title: Platelet Factor 4 Antibody Persistence and Long-term Pathogenicity in Vaccine-induced Immune Thrombotic Thrombocytopenia
Authors: Adam Kanack, Emily Mauch, Guillaume Roberge, Noah Splinter, Krishna Gundabolu, Geoffrey D. Wool, Gemlyn George, Mouhamed Yazan Abou-Ismail, Kristi J. Smock, David L. Green, Jonathan Coker, Mindy C. Kohlhagen, David L. Murray, Anand Padmanabhan
Keep up with Hemostasis Today.
-
Jan 14, 2026, 11:26Pablo Albasanz-García and Colleagues on Anticancer Treatment-Induced Arterial and Venous Thrombosis
-
Jan 14, 2026, 11:16ISTH 2026: Laurent Bertoletti To Serve as Vice Theme Leader for VTE
-
Jan 14, 2026, 11:08Leni von Bonsdorff Invites You to Hear and Learn The Latest News in The Plasma Field
-
Jan 14, 2026, 05:56Arun V J on The “Whole Blood” Nostalgia Trap
-
Jan 13, 2026, 16:38Caitlin Raymond: Understanding TAMOF as a TTP-Like Process
-
Jan 13, 2026, 15:22John Amako: Childhood to Adulthood Management Approach for SCD
-
Jan 13, 2026, 13:03Claudio Laudani on Dual Versus Single Antiplatelet Therapy
-
Jan 13, 2026, 12:46Stephanie Carlin and Colleagues on Clinical Outcomes of DOAC-Anticonvulsant Coprescription
-
Jan 13, 2026, 10:53Lena Volland on Ming Y Lim’s Example of Designing Care Models for WGBD Community With Intention